Pharsight

Auvelity generic

Auvelity is an antidepressant medication owned by Axsome. Comprising Bupropion Hydrochloride and Dextromethorphan Hydrobromide, Auvelity was first authorized for market use on 18 August, 2022. The drug is typically available in tablet, extended release;oral dosage forms.

When will Auvelity generic be available?

The generics of Auvelity can be made available after the expiry of its last patent, which will occur on 23 February, 2043. This is the patent titled 'Compounds and combinations thereof for treating neurological and psychiatric conditions.' Hence, Auvelity generic could potentially be released after this date.

Auvelity uses

Auvelity is utilized in the treatment of major depressive disorder. Its active ingredients, dextromethorphan and bupropion, work synergistically to increase dextromethorphan plasma levels, which enhances its effectiveness in alleviating depression symptoms.

Auvelity patent expiration

Auvelity holds a total of 110 patents, none of which have expired as of now. The last patent for Auvelity, titled 'Compounds and combinations thereof for treating neurological and psychiatric conditions', is anticipated to expire on 23 February, 2043. Below are the details of the patent:

EPO Oppostions filed on Auvelity

Auvelity dosage

Want to ask something?